nach oben

Clinical and Translational Oncology

Erschienen in:

31.01.2017 | Brief Research Article

Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy

verfasst von: L. de la Cueva, P. Lloro, M. J. Sangrós, L. López Vélez, P. Navarro, L. Sarria, S. Álvarez, D. Abós

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe the frequency of head and/or pancreas uncinate process uptake of 99mTc-HYNIC-TOC, to study its nature, and analyze its diagnostic value.

Materials and methods

Retrospective evaluation of 47 consecutive 99mTc-HYNIC-TOC examinations was conducted. Head and/or pancreas uncinate process uptake was considered to be physiological in patients with normal CT at the same episode and in follow-up. It was analyzed if age or diabetes mellitus was justifying the existence or not of uptake.

Results

32.5% patients showed uptake; 73% of them were mild. 84.6% patients with uptake have no pathology and 4% had neuroendocrine pancreatic disease at CT. Neither the age nor the diabetes mellitus established differences in patients without lesion.

Conclusions

Near one-third of patients show physiological uptake by head and/or pancreas uncinate process at 99mTc-HYNIC-TOC scintigraphy. It seems that neither the diabetes nor the ages are factors that determine this physiological uptake.

Bangard M, Béhé M, Bender H, Guhlke S, Willkomm P, Risse J, et al. Technetium-99m-octreotide for the detection of somatostatin receptor positive (SSTR+) tumors: preliminary results [abstract]. Eur J Nucl Med. 1998;25:837.CrossRef

Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new [99mTc]-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111 in-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27:628–37.CrossRefPubMed

Hubalewska-Dydejczyk A, Fröss-Baron K, Mikołajczak R, Maecke HR, Huszno B, Pach D, et al. [99mTc]-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years experience. Eur J Nucl Med Mol Imaging. 2006;33:1123–33.CrossRefPubMed

Kunikowska J, Królicki L, Pawlak D, Zerizer I, Mikołajczak R. Semiquantitative analysis and characterization of physiological biodistribution of (68) Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2012;37:1052–7.CrossRefPubMed

Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls and pitfalls in interpretation. RadioGraphics. 2015;35:500–16.CrossRefPubMed

Mapelli P, Tam HH, Sharma R, Aboagye EO, Al-Nahhas A. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging. Nucl Med Commun. 2014;35:613–9.CrossRefPubMed

Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med. 2012;37:57–62.CrossRefPubMed

Castellucci P, Ucha JP, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52:886–90.CrossRefPubMed

Jacobsson H, Larsson P, Jonsson C, Jussing E, Grybäck P. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET. Clin Nucl Med. 2012;37:362–5.CrossRefPubMed

10.

Chondrogiannis S, Grassetto G, Marzola MC, Rampin L, Massaro A, Bellan E, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33:179–84.CrossRefPubMed

11.

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.CrossRefPubMed

12.

Yamaga LY, Neto GC, da Cunha ML, Osawa A, Oliveira JC, Fonseca RQ, et al. [99mTc]-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT. Radiol Med. 2016;121:225–8.CrossRefPubMed

13.

Koçyiğit Deveci E, Ocak M, Bozkurt MF, Türker S, Kabasakal L, Uğur O. The diagnostic efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in comparison with 111 in-pentetrotide in the detection of neuroendocrine tumours. Mol Imaging Radionucl Ther. 2013;22:76–84.CrossRefPubMedPubMedCentral

14.

Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111 in-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708–16.PubMed

15.

Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: monodose evaluation and comparison with 111 in-octreotide. J Nucl Med. 2000;41:114–9.

16.

Sako T, Hasegawa K, Nishimura M, Kanayama Y, Wada Y, Hayashinaka E, et al. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement. Biochem Biophys Res Commun. 2013;442:79–84.CrossRefPubMed

17.

Krenning EP, de Jong M, Kooij PPM, Breeman WAP, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10:S23–9.CrossRefPubMed

18.

Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE1, Reubi JC, Kwekkeboom DJ, Krenning EP. Gastroenterology. 2010;139:742–53.CrossRefPubMed

19.

Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.CrossRefPubMed

20.

Unger N, Ueberberg B, Schulz S, Saeger W, Mann K, Petersenn S. Differential expression of somatostatin receptor subtype 1-5 proteins in numerous normal human tissues. Exp Clin Endocrinol Diabetes. 2012;120:482–9.CrossRefPubMed

21.

Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes of radiotracers selected for scintigraphic and radiotherapeutic somatostatin SST1-SST5 use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed

22.

Kunikowska J, Królicki L. PET receptor imaging in clinical oncology. Nucl Med Rev. 2012;15:C61–3.CrossRef

23.

Gandomkar M, Najafi R, Rabbani M. 99mTc-EDDA-Tricine-HYNIC-TOC versus 99mTc-EDDA-Tricine-HYNIC-TATE: synthesis and monodose result of two new radiopharmaceuticals for somatostatin receptor scintigraphy. International Atomic Energy Agency, Division of Physical and Chemical Sciences and Division of Human Health, Vienna (Austria); 2005. p. 348, 180; ISTR-2005: International symposium on trends in radiopharmaceuticals; Vienna (Austria); 14–18 Nov 2005; IAEA-CN-130; IAEA-CN-130/096P.

24.

Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80–7.CrossRefPubMed

25.

O’Sullivan AW, Heaton N, Rela M. Cancer of the uncinate process of the pancreas: surgical anatomy and clinicopathological features. Hepatobiliary Pancreat Dis Int. 2009; 8(6):569–74.

26.

Gersell DJ, Gingerich RL, Greider MH. Regional distribution and concentration of pancreatic polypeptide in the human and canine pancreas. Diabetes. 1979;28:11–5.CrossRefPubMed

27.

Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol. 2000;8:126–32.PubMed

28.

Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological and pathological processes in PET/CT uptake. Eur J Nucl Med Mol Imaging. 2013;40:514–23.CrossRefPubMed

29.

Prasad V, Baum PR. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumour lesions. Q J Nucl Med Mol Imaging. 2010;54:61–7.PubMed

30.

Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept. 2013;2013:926295. doi:10.1155/2013/926295.CrossRefPubMedPubMedCentral

Titel: Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy
verfasst von: L. de la Cueva
P. Lloro
M. J. Sangrós
L. López Vélez
P. Navarro
L. Sarria
S. Álvarez
D. Abós
Publikationsdatum: 31.01.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 7/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1616-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy

Abstract

Purpose

Materials and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Predictive factors for survival in neoadjuvant radiochemotherapy for advanced rectal cancer

Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential

Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma

Topography of the sentinel node according to the affected lobe in lung cancer

Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies

Retroperitoneal lymph node dissection: an update in testicular malignancies

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie